Latest Breaking News On - United therapeutics corporation nasdaq - Page 1 : vimarsana.com

Ferrer Obtains the Distribution Rights for Treprostinil Inhalation Solution Including the Potential Indications for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)

The international pharmaceutical BCorp company Ferrer continues to strengthen its focus on pulmonary vascular and interstitial lung diseases by announcing the expansion of its current distribution agreement

Ferrer Secures Distribution Rights for Treprostinil, Targets IPF and PPF

Ferrer Obtains the Distribution Rights for Treprostinil Inhalation Solution Including the Potential Indications for Idiopathic Pulmonary Fibrosis IPF and Progressive Pulmonary Fibrosis PPF

The international pharmaceutical BCorp company Ferrer continues to strengthen its focus on pulmonary vascular and interstitial lung diseases by announcing the expansion of its current distribution agreement with United Therapeutics Corporation for Tyvaso a pharmaceutical drugdevice combination product authorized for the treatment of WHO Group 3 Pulmonary Hypertension associated with Interstitial Lung Disease PHILD and for WHO Group 1 Pulmonary Arterial Hypertension PAH.

CORRECTING and REPLACING PHOTO United Therapeutics Announces World's First Successful Xenothymokidney Transplant

United Therapeutics Announces World's First Successful Xenothymokidney Transplant

United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program

Repurchase reflects the strength of United Therapeutics’ balance sheet and confidence in its near-term prospects .

United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference

United Therapeutics Corporation , a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s.

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results

United Therapeutics Corporation , a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2023. Full year 2023 revenues rose to a record $2.33.

United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process

United Therapeutics Corporation announced today the commencement of litigation with the United States Food and Drug Administration . In the litigation, United Therapeutics alleges that the FDA.

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2023 Financial Results Before the Market Opens on Wednesday, February 21, 2024

United Therapeutics Corporation , announced today that it will report its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 21, 2024. United.